S. Millar

发表

Treatment complexity in cystic fibrosis: trends over time and associations with site-specific outcomes.

G. Sawicki, A. Quittner, M. Konstan, 2013, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Design and powering of cystic fibrosis clinical trials using rate of FEV(1) decline as an efficacy endpoint.

M. Konstan, D. Pasta, D. VanDevanter, 2010, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Disease burden in people with cystic fibrosis heterozygous for F508del and a minimal function mutation.

G. Sawicki, M. Konstan, P. Flume, 2021, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Burden of cystic fibrosis in children <12 years of age prior to the introduction of CFTR modulator therapies

S. Millar, E. Arteaga‐Solis, K. Bresnick, 2021, BMJ Open Respiratory Research.

Rapid lung function decline in adults with early-stage cystic fibrosis lung disease.

D. Sanders, D. Pasta, M. Schechter, 2019, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Cystic fibrosis clinical characteristics associated with dornase alfa treatment regimen change

W. Morgan, M. Konstan, D. Pasta, 2018, Pediatric pulmonology.

Lung function decline is delayed but not decreased in patients with cystic fibrosis and the R117H gene mutation.

C. Goss, G. Sawicki, W. Morgan, 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study.

C. Goss, G. Sawicki, D. Waltz, 2017, The Lancet. Respiratory medicine.

Probability of treatment following acute decline in lung function in children with cystic fibrosis is related to baseline pulmonary function.

W. Morgan, M. Konstan, D. Pasta, 2013, The Journal of pediatrics.

Clinical use of dornase alfa is associated with a slower rate of FEV1 decline in cystic fibrosis

W. Morgan, M. Konstan, D. Pasta, 2011, Pediatric pulmonology.

Clinical use of tobramycin inhalation solution (TOBI®) shows sustained improvement in FEV1 in cystic fibrosis

W. Morgan, M. Konstan, D. Pasta, 2014, Pediatric pulmonology.

Patients with Cystic Fibrosis and a G551D or Homozygous F508del Mutation: Similar Lung Function Decline.

G. Sawicki, M. Konstan, D. Pasta, 2017, American journal of respiratory and critical care medicine.

Relationship of Antibiotic Treatment to Recovery after Acute FEV1 Decline in Children with Cystic Fibrosis

W. Morgan, M. Konstan, D. Pasta, 2017, Annals of the American Thoracic Society.

Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint.

W. Morgan, M. Konstan, D. Pasta, 2011, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

EFFECT OF ELEXACAFTOR/TEZACAFTOR/IVACAFTOR ON ANNUAL RATE OF LUNG FUNCTION DECLINE IN PEOPLE WITH CYSTIC FIBROSIS.

G. Sawicki, M. Jennings, J. Altenburg, 2022, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Long-term effects of pregnancy and motherhood on disease outcomes of women with cystic fibrosis.

A. Quittner, M. Konstan, D. Pasta, 2013, Annals of the American Thoracic Society.

Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.

G. Sawicki, R. Fischer, C. Owen, 2021, The Lancet. Respiratory medicine.

Sustained Benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data.

G. Sawicki, M. Konstan, D. Pasta, 2015, American journal of respiratory and critical care medicine.

Comparison of FEV1 reference equations for evaluating a cystic fibrosis therapeutic intervention

W. Morgan, M. Konstan, D. Pasta, 2017, Pediatric pulmonology.

Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial

M. Dimopoulos, R. Hájek, M. Delforge, 2013, Leukemia & lymphoma.

Early childhood wheezing is associated with lower lung function in cystic fibrosis

M. Rosenfeld, W. Morgan, M. Konstan, 2012, Pediatric pulmonology.

Lung function changes before and after pulmonary exacerbation antimicrobial treatment in cystic fibrosis

W. Morgan, M. Konstan, D. Pasta, 2019, Pediatric pulmonology.

Rate of Lung Function Decline in People with Cystic Fibrosis Having a Residual Function Gene Mutation

C. Goss, G. Sawicki, W. Morgan, 2022, Pulmonary Therapy.

Socioeconomic status and the likelihood of antibiotic treatment for signs and symptoms of pulmonary exacerbation in children with cystic fibrosis.

S. McColley, W. Morgan, M. Konstan, 2011, The Journal of pediatrics.

Pulmonary exacerbations and acute declines in lung function in patients with cystic fibrosis.

W. Morgan, M. Konstan, D. Pasta, 2018, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Comparative effectiveness of cladribine tablets versus fingolimod in the treatment of highly active multiple sclerosis: A real-world study.

W. Brownlee, G. Harty, B. Hayward, 2023, Multiple sclerosis and related disorders.

Reduced heart failure-related healthcare costs with Furoscix versus in-hospital intravenous diuresis in heart failure patients: the FREEDOM-HF study.

D. Bensimhon, W. Weintraub, W. Peacock, 2023, Future cardiology.

ePS03.4 Improved rate of decline in percent predicted FEV1 (ppFEV1) is not associated with acute improvement in ppFEV1 in patients with cystic fibrosis (CF) treated with ivacaftor

G. Sawicki, M. Konstan, D. Pasta, 2016 .

Long-term effects of pregnancy and motherhood on disease outcomes of women with cystic fibrosis.

A. Quittner, M. Konstan, D. Pasta, 2013, Annals of the American Thoracic Society.